Start Time: 16:30 January 1, 0000 5:21 PM ET
Ardelyx, Inc. (NASDAQ:ARDX)
Q4 2023 Earnings Conference Call
February 22, 2024, 16:30 PM ET
Company Participants
Mike Raab - President and CEO
Justin Renz - Chief Financial and Operations Officer
Laura Williams - CMO
Susan Rodriguez - Chief Commercial Officer
Caitlin Lowie - VP of Corporate Communications and IR
Conference Call Participants
Dennis Ding - Jefferies
Chris Raymond - Piper Sandler
Laura Chico - Wedbush
Louise Chen - Cantor Fitzgerald
Yigal Nochomovitz - Citi
Ryan Deschner - Raymond James
Joseph Thome - TD Cowen
Thomas Yip - H.C. Wainwright
Matt Kaplan - Ladenburg Thalmann
Operator
Welcome to the Ardelyx Fourth Quarter and Full Year 2023 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded.
I would now like to turn the conference over to Caitlin Lowie, Vice President of Corporate Communications and Investor Relations at Ardelyx. Please go ahead.
Caitlin Lowie
Thank you. Good afternoon and welcome to our fourth quarter and full year 2023 financial results call. During this call, we will refer to the press release issued earlier today, which is available on the investor section of the company's website at ardelyx.com.
During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review the risk factors in our most recent annual report on Form 10-K that was filed today. It can be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our views change.
Our President and CEO, Mike Raab, will begin today's call with opening remarks and an overview of the company's progress during the fourth quarter of 2023 and the full year 2023. Next, Susan Rodriguez, Chief Commercial Officer, will provide an update on the performance of IBSRELA and XPHOZAH.
Our Chief Medical Officer, Dr. Laura Williams, will then discuss and expose the real-world evidence study announced today. Justin Renz, Chief Financial and Operations Officer, will conclude today's prepared remarks with a review of the company's financial performance during the fourth quarter and full year ended December 31, 2023, before we open the call to questions.